Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Antihyperlipidemic Potential of Balarishta Prepared by Traditional and Modern Methods in High Fat Diet Induced Hyperlipidemic Rats


Affiliations
1 Dr. K. N. Modi Institute of Pharmaceutical Education and Research, Modinagar, Uttar Pradesh, India
     

   Subscribe/Renew Journal


The objective of the present study was to evaluate the lipid peroxidation activity and related antihyperlipidemic activity of Balarishta-T and Balarishta-M prepared by traditional and modern methods and its marketed formulation in high fat diet induced hyperlipidemic rats. The antioxidant activity of Balarishta-T and Balarishta-M was increased in concentration dependent manner. Balarishta-T and Balarishta-M inhibited the ferrous sulphate induced lipid peroxidation in a dose dependent manner and showed inhibitory concentration (IC50) value 196.61 μg/ml and 201.72 μg/ml respectively. Oral administration of Balarishta-T and Balarishta-M for nine weeks at the dose of 2 ml/kg significantly reduced serum cholesterol, serum LDL and serum triglycerides while showed significant rise in serum HDL as compared to high fat diet fed control group. Marketed Balarishta also showed significant decrease in serum cholesterol, serum LDL, serum triglycerides and showed significant rise in serum HDL. Atorvastatin (1.2 mg/kg, p.o.) was used as standard antihyperlipidemic drug. Both types of Balarishta as Balarishta-T and Balarishta-M showed significant reduction in atherogenic index as compared to high fat diet fed control group which strongly supports antiatherosclerotic property of Balarishta.

Keywords

Balarishta, Lipid Per Oxidation, Atherogenic Index, Antihyperlipidemic Activity, Atorvastatin.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Tripathi. K.D. Essentials of Medical Pharmacology. 4th Edition, published by Jaypee Brothers, New Delhi, 2002; 612-614.
  • Singh N, Kapur KK and Singh SP. Mechanism of cardiovascular action of Terminalia arjuna . J Med Plant Res. 1982; 45:102-104.
  • The Ayurvedic Formulary of India, Part-I. 2000, 1st edition, The Controller of Publications, Delhi, 17.
  • Prakash A, Verma RK, Ghosal S. Alkaloid constituents of Sida acuta, Sida humilis, S. rhombifolia and Sida spinosa. Planta Medica 1981;43:384-388.
  • Ghosal S, Chauhan RR, Mehta R. Chemical constituents of Malvaceae, Alkaloids of Sida cordifolia. Phytotherapy Research 1975;14:830-832.
  • Sutradhar RK, Rahman AM, Ahmad M, Bachar SC. Bioactive flavones of Sida cordifolia. Phytotherapy Letters 2008;1(4):179-182.
  • Sutradhar RK, Rahman AM, Ahmad M, Bachar SC, Saha A. Analgesic and anti-inflammatory principle from Sida cordifolia Linn. Journal of Biological Sciences 2006;6(1):160-163.
  • Budhiraja RD, Sudhir S. Review of biological activity of withanolides. Journal of Science and Industrial Research 1987;46:488.
  • Andallu B, Radhika B. Hypoglycemic, diuretic and hypocholesterolemic effect of winter cherry (Withania somnifera, Dunal) root. Indian Journal of Experimental Biology 2000;38:607-609.
  • Mishra S. Bhaisazya Kalpana Vigyan. Varanasi, India: Chaukambha Surbharati Prakashan; 2005.p. 253-254.
  • Alam M, Radhamani S, Ali U and Purushottam KK. Microbiological Screening of Dhataki flowers. Journal of Research in Ayurveda and Siddha 1984; 2(4):371-375.
  • Ohkawa H, Oshishi N and Yagi K. Assay for lipid peroxidation in animal tissues by thiobarbituricacid. Analytical Biochemistry 1979; 95:351.
  • Lowery OH, Rosenbrough NJ, Farr AL and Randall RJ. Protein estimation with Folin phenol reagent. Biol Chem. 1951;193:265-275.
  • Khanna AK, Chander R and Kapoor NK. Terminala arjuna: an Ayurvedic cardiotonic, Regulates lipid metabolism in Hyperlipidemic rats. Phytother Res. 1996;10: 663-665.
  • Allain CC, Poon LS, Chan CS and Richmond W. Enzymatic Determination of Total Serum cholesterol. Clin Chem .1974;20::447-475.
  • Friedewald WT, Levy RI and Fredrickson DS. Estimation of concentration of low density cholesterol in plasma without use of ultracentrifuge. J Clin Chem .1972;18: 449-502.
  • Muller PH, Schmulling RM, Liebich HM and Eggstein M. A fully Enzymatic Triglyceride Determination. J Clin Chem. 1977;15:457-464.
  • Anne SM, Ock SY, Debra AP, Andrew LW and Edwin NF. Inhibition of Human Low Density Lipoprotein oxidation in relation to composition of Phenolic antioxidants in Grapes (Vitis Vinifera). J Agri Food Chem. 1997;45 (5):1638-1643.
  • S Renaud, and M De Lorgeril. Wine, alcohol, Platelets and the French Paradox for Coronary Heart Disease. The Lancet. 1992; 339: 1523-1526.
  • Pederson TR. Low- density lipoprotein cholesterol lowering is and will be the key to the future of lipid management. American J Cardiol. 2001; 87(5A): 8B-12B.
  • Boden WE and Pearson TA. Raising low levels of High Density Lipoprotein Cholesterol is an important target of therapy. American J cardiol. 2000; 85(5):645-650.

Abstract Views: 111

PDF Views: 2




  • Antihyperlipidemic Potential of Balarishta Prepared by Traditional and Modern Methods in High Fat Diet Induced Hyperlipidemic Rats

Abstract Views: 111  |  PDF Views: 2

Authors

Preeti Tiwari
Dr. K. N. Modi Institute of Pharmaceutical Education and Research, Modinagar, Uttar Pradesh, India

Abstract


The objective of the present study was to evaluate the lipid peroxidation activity and related antihyperlipidemic activity of Balarishta-T and Balarishta-M prepared by traditional and modern methods and its marketed formulation in high fat diet induced hyperlipidemic rats. The antioxidant activity of Balarishta-T and Balarishta-M was increased in concentration dependent manner. Balarishta-T and Balarishta-M inhibited the ferrous sulphate induced lipid peroxidation in a dose dependent manner and showed inhibitory concentration (IC50) value 196.61 μg/ml and 201.72 μg/ml respectively. Oral administration of Balarishta-T and Balarishta-M for nine weeks at the dose of 2 ml/kg significantly reduced serum cholesterol, serum LDL and serum triglycerides while showed significant rise in serum HDL as compared to high fat diet fed control group. Marketed Balarishta also showed significant decrease in serum cholesterol, serum LDL, serum triglycerides and showed significant rise in serum HDL. Atorvastatin (1.2 mg/kg, p.o.) was used as standard antihyperlipidemic drug. Both types of Balarishta as Balarishta-T and Balarishta-M showed significant reduction in atherogenic index as compared to high fat diet fed control group which strongly supports antiatherosclerotic property of Balarishta.

Keywords


Balarishta, Lipid Per Oxidation, Atherogenic Index, Antihyperlipidemic Activity, Atorvastatin.

References